Abstract Purpose of Review Metastatic prostate cancer is a lethal and highly heterogeneous
malignancy, associated with a broad spectrum of potentially actionable molecular …

Background Cabazitaxel improves overall survival (OS) in metastatic castration-resistant
prostate cancer (mCRPC) patients progressing after docetaxel. In this prospective study, we …

PURPOSE Cell-free DNA (cfDNA) and circulating tumor cell (CTC)–based liquid biopsies
have emerged as potential tools to predict responses to androgen receptor (AR)–directed …

Castration resistance is in part attributable to aberrant activation of androgen receptor (AR)
signaling by the intracrine activation of androgen precursors derived from adrenal glands …

Prostate cancer, the second most common cancer found in male over the world, was
estimated to have 191,930 new cases and 33,330 deaths in 2020 in the United States …

Peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-
1α/PPARGC1A) is a pivotal transcriptional coactivator involved in the regulation of …

Androgen‐deprivation therapy is a standard treatment for advanced prostate cancer.
However, most patients eventually acquire resistance and progress to castration‐resistant …

Introduction: The androgen receptor variant AR-V7 is gaining attention as a potential
predictive marker for as well as one of the resistance mechanisms to the most current anti …

Simple Summary Prostate cancer research has been recently characterized by the discovery
of several prognostic and predictive molecular factors, which ultimately improve patients' …

Recently, mixed forms between adenocarcinoma and neuroendocrine prostate cancer
(NEPC) have emerged that are characterized by persistent androgen receptor (AR) …